ライフサイエンスコーパス: cardiac death

1 milies (230 relatives, 80 unexplained sudden cardiac death).

2 at the greatest risk of sudden and nonsudden cardiac death.

3 ardioverter-defibrillator shocks, and sudden cardiac death.

4 ive value of 99.9% (95% CI, 99.7%-99.9%) for cardiac death.

5 All-cause mortality and sudden cardiac death.

6 ypertrophy are major risk factors for sudden cardiac death.

7 arrhythmias and an increased risk of sudden cardiac death.

8 linked to ventricular arrhythmias and sudden cardiac death.

9 as hospitalization for heart failure and/or cardiac death.

10 dia, aborted sudden cardiac death, or sudden cardiac death.

11 terventions with potential to prevent sudden cardiac death.

12 S) may manifest as arrhythmia or even sudden cardiac death.

13 e junction and are a leading cause of sudden cardiac death.

14 o impaired mechanical contraction and sudden cardiac death.

15 D) in the treatment and prevention of sudden cardiac death.

16 repolarization and are susceptible to sudden cardiac death.

17 nvasive cardiovascular procedures, or sudden cardiac death.

18 and treatment of patients at risk of sudden cardiac death.

19 indicator for cardiac arrhythmias and sudden cardiac death.

20 diac death as compared with explained sudden cardiac death.

21 ns of heart disease and can result in sudden cardiac death.

22 cause of mortality on hemodialysis is sudden cardiac death.

23 indicator for cardiac arrhythmias and sudden cardiac death.

24 sk factor for cardiac arrhythmias and sudden cardiac death.

25 iated with delayed repolarization and sudden cardiac death.

26 trial or ventricular arrhythmias, and sudden cardiac death.

27 myocardial infarction and 6 (17%) as sudden cardiac death.

28 group known to have elevated rates of sudden cardiac death.

29 spitalizations, ventricular arrhythmias, and cardiac death.

30 chemia-associated QT prolongation and sudden cardiac death.

31 rdiac hypertrophy, heart failure, and sudden cardiac death.

32 creased risk of aortic valve replacement and cardiac death.

33 argeting these factors decreases the risk of cardiac death.

34 mechanisms of arrhythmias leading to sudden cardiac death.

35 mplantation for primary prevention of sudden cardiac death.

36 indicated for prevention of secondary sudden cardiac death.

37 d increased unipolar penumbra area predicted cardiac death.

38 ted cardiac disorders associated with sudden cardiac death.

39 ular arrhythmias, cardiac arrest, and sudden cardiac death.

40 sease (CAD), identifies patients at risk for cardiac death.

41 ance the science and clinical care of sudden cardiac death.

42 dying arrhythmic disorders leading to sudden cardiac death.

43 ions lead to heart attack, stroke, or sudden cardiac death.

44 oal of treatment is the prevention of sudden cardiac death.

45 arget vessel myocardial infarction, TLR, and cardiac death.

46 heart rhythm disorder associated with sudden cardiac death.

47 ading to ventricular fibrillation and sudden cardiac death.

48 , which in turn predisposes to VA and sudden cardiac death.

49 rillators, which have no impact on nonsudden cardiac death.

50 d syncope, aborted cardiac arrest, or sudden cardiac death.

51 tachycardia (VT) is a major cause of sudden cardiac death.

52 myocardial injury, cardiomyopathy, and even cardiac death.

53 cular tachycardia >240 bpm) and 36 nonsudden cardiac deaths.

54 ted to myocardial infarction (MI), and other cardiac deaths.

55 rdiovascular causes, of which 15 were sudden cardiac deaths.

56 .15 to 1.46; P < .001) on the basis of 1,253 cardiac deaths.

57 evascularized patients showed lower rates of cardiac death (0.6% vs. 4.3%, respectively; p < 0.001),

58 the highest incidence of unexplained sudden cardiac death (0.8 cases per 100,000 persons per year).

59 and not associated with arrhythmia or sudden cardiac death (0.95 [0.76-1.19]).

60 confidence interval [CI]: 3.25 to 7.16) and cardiac death (1.0% vs. 0.2%; OR: 5.87; 95% CI: 3.60 to

61 (hazard ratio [95% confidence interval]) of cardiac death (1.45 [1.24 to 1.69]), sudden cardiac deat

62 cardiac death (1.45 [1.24 to 1.69]), sudden cardiac death [1.70 (1.34 to 2.15)], first cardiovascula

63 est predictor for all-cause death and sudden cardiac death (10.09%, 95% CI 4.72-20.42% and 16.44%, 95

64 When the analyses were limited to cardiac death (1S-PCI: n = 9 [3.41%] vs. MS-PCI: n = 14

65 5-6.5; P=0.425) and its singular components (cardiac death: 2.8% versus 2.0%, hazard ratio, 1.3; 95%

66 s of age had the highest incidence of sudden cardiac death (3.2 cases per 100,000 persons per year),

67 t (69%), aortic valve replacement (67%), and cardiac death (4%).

68 cular arrhythmias (82%); and frequent sudden cardiac death (40 cases in 21 of 28 families).

69 Unexplained sudden cardiac death (40% of cases) was the predominant finding

70 ifferences were noted in the rates of 1-year cardiac death (44 [4.0%] for the bivalirudin group vs 48

71 (5.8% vs. 9.6%, respectively; p = 0.008) and cardiac death (5.3% vs. 9.0%, respectively; p = 0.003),

72 y normal heart carries a low risk for sudden cardiac death; accordingly, there is typically no indica

73 Cardiac deaths accounted for 46% of all deaths, whereas

74 For the first time, risk estimates of cardiac death after each cancer diagnosed between the ag

75 aHR: 1.95; 95% CI: 1.11 to 3.41), and sudden cardiac death (aHR: 3.75; 95% CI: 1.26 to 11.2) over a m

76 increases risk of cardiovascular and sudden cardiac death, although the underlying mechanisms are un

77 ever, the recognition of the risk for sudden cardiac death among basketball players is challenging be

78 d autopsy information on all cases of sudden cardiac death among children and young adults 1 to 35 ye

79 Sudden cardiac death among children and young adults is a devas

80 identification of a possible cause of sudden cardiac death among children and young adults.

81 -based, clinical and genetic study of sudden cardiac death among children and young adults.

82 ucing risk of all-cause mortality and sudden cardiac death among patients with an EF </=35% at baseli

83 ation was nonlinear and significant only for cardiac death among patients with TMAO concentrations be

84 ad a 4-fold higher risk of cardiac or sudden cardiac death and a 2-fold higher risk of any-cause deat

85 The secondary outcomes were sudden cardiac death and cardiovascular death.

86 Donor after cardiac death and donor after brain stem death (DBD) had

87 ardial fibrosis predicts both risk of sudden cardiac death and likelihood of LV functional recovery,

88 y with long-term follow-up, (aborted) sudden cardiac death and mortality rates were found to be simil

89 ost-TAVR is a marker of an increased risk of cardiac death and need for PPI at 1-year follow-up.

90 Primary end point was a composite of cardiac death and nonfatal myocardial infarction.

91 d predictor (hazard ratio, 4.86; P<0.01) for cardiac death and nonfatal myocardial infarction.

92 Modes of death were divided into sudden cardiac death and nonsudden death and compared between p

93 prediction and prevention of SCA and sudden cardiac death and provides justification for a research

94 For this review, we analyzed data on sudden cardiac death and SCA available from population studies

95 The primary focus has been sudden cardiac death and the utility of screening with or witho

96 ur analyses, whereas the composite of sudden cardiac death and ventricular tachycardia requiring trea

97 125 patients experienced 136 hard events (18 cardiac deaths and 118 nonfatal myocardial infarction).

98 successfully resuscitated cardiac death, or cardiac death) and events were significantly reduced in

99 the incidence of subsequent heart failure or cardiac deaths) and increased health-care costs when the

100 nd nonfatal myocardial infarction and sudden cardiac death), and harms.

101 everity expression, high-incidence of sudden cardiac death, and absence of skeletal myopathy or condu

102 of interest were myocardial infarction (MI), cardiac death, and all-cause mortality within 30 days af

103 use mortality, heart transplantation, sudden cardiac death, and appropriate implantable cardioverter

104 Heart failure, cardiac death, and cardiac dysfunction were infrequent i

105 required due to an elevated risk for sudden cardiac death, and catheter ablation can be used as adju

106 point of nonfatal myocardial infarction and cardiac death, and medical costs.

107 ycardia, syncope, a family history of sudden cardiac death, and severe cardiac hypertrophy are major

108 II/IV symptoms, aortic valve replacement, or cardiac death, and to compare AE rates between MAVD and

109 pitalizations, 10 ventricular arrhythmias, 5 cardiac deaths, and 5 thromboembolic events).

110 A clinical combined endpoint of cardiac death, appropriate implantable cardioverter-defi

111 ibrillators for primary prevention of sudden cardiac death are less likely to experience sustained ve

112 sustained ventricular arrhythmias and sudden cardiac death are lower in women than in men.

113 ustained ventricular arrhythmias, and sudden cardiac death are recognized.

114 compared with other etiologies, with sudden cardiac death as an important mode of death.

115 pendently associated with unexplained sudden cardiac death as compared with explained sudden cardiac

116 There has been a decrease in aborted sudden cardiac death as the first manifestation of the disease

117 on an estimate of a patient's risk of sudden cardiac death, as well as their preferences and values.

118 These sudden cardiac deaths associated with Lyme carditis occurred fr

119 farction, or type 1 myocardial infarction or cardiac death at 30 days.

120 tion, or subsequent myocardial infarction or cardiac death at 30 days.

121 nfarction or type 1 myocardial infarction or cardiac death at 30 days.

122 primary outcome was myocardial infarction or cardiac death at 30 days.

123 There were no cardiac deaths at 30 days and 7 (0.1%) at 1 year, with a

124 , 1 myocardial infarction at 30 days, and no cardiac deaths at 30 days).

125 nting with myocardial infarction and 75 (2%) cardiac deaths at 30 days.

126 c and histologic studies (unexplained sudden cardiac death), at least 59 cardiac genes were analyzed

127 families who experienced unexplained sudden cardiac death before 45 years of age were included from

128 ciated with a significant decrease in infant cardiac deaths between 2007 and 2013 compared with state

129 ged as a novel tool for prevention of sudden cardiac death, but clinical performance data for adults

130 rove survival in patients at risk for sudden cardiac death, but complications remain an important dra

131 nded at autopsy in suspected cases of sudden cardiac death, but data on the role of nonselective post

132 myopathy (ARVC) is a leading cause of sudden cardiac death, but its progression over time and predict

133 on channel, have been associated with sudden cardiac death, but only a subset of these variants have

134 eptor-2 (RyR2) gene in both SUDEP and sudden cardiac death cases linked to catecholaminergic polymorp

135 Although rare, sudden cardiac death caused by Lyme disease might be an under-r

136 Hypertension is a risk factor for sudden cardiac death caused by ventricular tachycardia and fibr

137 studies showed its prognostic value for both cardiac death (CD) and sudden death.

138 fter DES-PCI had an increased risk of MI and cardiac death compared with patients without IHD.

139 Increasingly, donation after cardiac death (DCD) donors are used in view of the organ

140 rience with liver grafts from donation after cardiac death (DCD) donors have resulted in reservations

141 jury (IRI) of renal allografts donated after cardiac death (DCD) in a porcine animal model of transpl

142 stablished complication after donation after cardiac death (DCD) kidney transplants, but the impact o

143 n after brain death (DBD) and donation after cardiac death (DCD) kidneys before donation, after cold

144 This group is often allocated a donor after cardiac death (DCD) liver as a solution for waiting time

145 Donation after cardiac death (DCD) to overcome the donor organ shortage

146 erebrovascular events, which were defined as cardiac death, death, reinfarction, rehospitalization fo

147 Noncardiac and any cardiac deaths did not differ significantly by treatment

148 ew article, part of the Compendium on Sudden Cardiac Death, discusses the major issues related to the

149 positive donors, livers from donation after cardiac death donors, livers with >30% steatosis, and li

150 Overall, 14 of 50 patients suffered a sudden cardiac death during follow-up, with a cumulative incide

151 Surgery increased 1.58x the risk of cardiac death during follow-up.

152 ection fraction for the prediction of sudden cardiac death events.

153 7, 1.6, 1.4, 1.3 and 1.2 times the number of cardiac deaths expected from the general population, res

154 Sudden cardiac death (fatal or aborted) was the primary end poi

155 For sudden cardiac death, FHSD, nsVT, and obstruction showed signif

156 low-up, survival free from VT recurrence and cardiac death for patients with LVEF>30% was 80% (95% co

157 at the mice developed CCD, leading to sudden cardiac death from complete heart block, but no longer d

158 Risk stratification in the context of sudden cardiac death has been acknowledged as one of the major

159 Although sudden cardiac death has been broadly studied, little is known

160 al, 1.18-2.01; P=0.002) but similar risks of cardiac death (hazard ratio, 1.41; 95% confidence interv

161 onfidence interval, 1.31 to 6.82) and sudden cardiac death (hazard ratio, 4.52; 95% confidence interv

162 versus CABG was an independent predictor of cardiac death (hazard ratio: 1.55; 95% confidence interv

163 ome patients are at increased risk of sudden cardiac death, heart failure, and atrial fibrillation.

164 alovirus seropositive status, donation after cardiac death, hepatitis B and C seropositive status, ci

165 ferred a higher risk of non-CV death, sudden cardiac death, hospitalization, CV hospitalization, and

166 idence intervals (CI), 1.02-1.09]; P=0.001), cardiac death (HR, 1.10 [95% CI, 1.05-1.17]; P<0.001), a

167 receive defibrillators was related to sudden cardiac death in 8.0% among those with ICM but in only 0

168 tly contributes to the high rates of LVH and cardiac death in CKD.

169 alysis examined data collected in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), which r

170 was assessed in the SCD-HeFT cohort (Sudden Cardiac Death in Heart Failure Trial; n=2521).

171 ally and patients at risk for SCA and sudden cardiac death in particular is limited by the diversity

172 D) is the standard therapy to prevent sudden cardiac death in patients with coronary artery disease a

173 is a well-established risk factor for sudden cardiac death in survivors of acute myocardial infarctio

174 nt risk stratification strategies for sudden cardiac death in the heart failure patient are not ideal

175 ity to alcohol, leading to sudden arrhythmic cardiac death in the second decade of life.

176 athy (ARVC) is a significant cause of sudden cardiac death in the young.

177 31 of 113 cases (27%) of unexplained sudden cardiac death in which genetic testing was performed.

178 It is also the most common cause of sudden cardiac death in young adults and a major cause of morbi

179 There were two cardiac deaths in arm A and one each in arms B and C.

180 anced HF and SCD accounted for two-thirds of cardiac deaths in patients after TAVR.

181 c syncope, aborted cardiac arrest, or sudden cardiac death) in LQT3 patients.

182 thmic events (LAE) (cardiac arrest or sudden cardiac death) in SQTS patients.

183 tes with cardiovascular mortality and sudden cardiac death independent of traditional risk factors in

184 Sudden cardiac death is a major contributor to mortality for ad

185 Sudden cardiac death is common in humans with restrictive cardi

186 The incidence of sudden cardiac death is higher in US basketball players compare

187 t occurrence of any of the following events: cardiac death, ischemic stroke, ventricular tachycardia/

188 the secondary combined ischemic endpoint of cardiac death, MI, definite stent thrombosis, and ischem

189 jor adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), target vessel

190 int target lesion failure was a composite of cardiac death, myocardial infarction (not related to oth

191 major adverse cardiac events, a composite of cardiac death, myocardial infarction, and clinically ind

192 assessed the incidence and the predictors of cardiac death, myocardial infarction, and serious bleedi

193 The primary end point was a composite of cardiac death, myocardial infarction, and stroke.

194 ac event (MACE) assessed as the composite of cardiac death, myocardial infarction, and target vessel

195 main clinical outcome measure (composite of cardiac death, myocardial infarction, and target vessel

196 ssed major adverse cardiac events, including cardiac death, myocardial infarction, ischemia-driven ta

197 primary outcome was time to composite event (cardiac death, myocardial infarction, or cardiac hospita

198 currence of MACE defined as the composite of cardiac death, myocardial infarction, or coronary revasc

199 postdischarge major adverse cardiac events (cardiac death, myocardial infarction, or ischemia-driven

200 diac events were defined as the composite of cardiac death, myocardial infarction, or stent thrombosi

201 e primary safety endpoint was a composite of cardiac death, myocardial infarction, or stent thrombosi

202 to surgery was independently associated with cardiac death/myocardial infarction.

203 the combined primary end point (composite of cardiac death, nonfatal myocardial infarction, and strok

204 Cardiac death occurred in 18 patients in the scaffold gr

205 Sudden cardiac death occurred in 24 patients (4.3%) in the ICD

206 Cardiac death occurred in 438 patients (2.5%), myocardia

207 One cardiac death occurred in each group (p=1.00).

208 the families in which an unexplained sudden cardiac death occurred.

209 erquartile range [IQR]: 17 to 36 months), 50 cardiac deaths occurred.

210 -0.98; P=0.004) and family history of sudden cardiac death (odds ratio, 3.5; 95% confidence interval,

211 r (3%) patients: one (<1%) patient died from cardiac death, one (<1%) patient had periprocedural myoc

212 C) is a hereditary disease leading to sudden cardiac death or heart failure.

213 ty of major adverse cardiac events (MACE) of cardiac death or myocardial infarction and the probabili

214 revascularization, including a reduction in cardiac death or myocardial infarction, as well as costs

215 e protocols specific to brain death (ie, not cardiac death or organ donation procedures).

216 Risk for cardiac death or rehospitalization for MI within 60 days

217 nts with Brugada syndrome and aborted sudden cardiac death or syncope have higher risks for ventricul

218 re (HR, 1.48; 95% CI, 1.43-1.53), and sudden cardiac death or ventricular arrhythmia (HR, 1.65; 95% C

219 nfarction, heart failure, stroke, and sudden cardiac death or ventricular arrhythmia.

220 The composite incidence of sudden cardiac death or ventricular tachycardia was 41% at 1 ye

221 jor arrhythmic events (sustained VAs, sudden cardiac death, or appropriate ICD therapy) in asymptomat

222 F hospitalization, successfully resuscitated cardiac death, or cardiac death) and events were signifi

223 a history of ventricular arrhythmias, sudden cardiac death, or implantable cardioverter-defibrillator

224 ined ventricular tachycardia, aborted sudden cardiac death, or sudden cardiac death.

225 ance of the condition and the risk of sudden cardiac death, other family members are tested for the g

226 er, HCM is also an important cause of sudden cardiac death, particularly in adolescents and young adu

227 eart muscle disorder, predisposing to sudden cardiac death, particularly in young patients and athlet

228 Gene delivery of Ang-(1-9) reduced sudden cardiac death post-MI.

229 tors (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patients with

230 ereas for patients >70 years old, the sudden cardiac death rate was 1.6 (95% CI, 0.8-3.2) and nonsudd

231 For patients </=70 years old, the sudden cardiac death rate was 1.8 (95% CI, 1.3-2.5) and nonsudd

232 ADIRs included cardiac death, reinfarction, and definite stent thrombos

233 95% confidence interval, 0.50-0.87), sudden cardiac death (relative hazard, 0.57; 95% confidence int

234 rs' preserved fluid from DCD (donation after cardiac death) renal transplantation and four isolates i

235 The relative rates of all-cause and cardiac death, revascularization, and target lesion fail

236 ase case, the complex epidemiology of sudden cardiac death risk and the substantial new funding requi

237 Using sudden cardiac death risk as a base case, the complex epidemiol

238 ion is whether a particular patient's sudden cardiac death risk is sufficient to justify placement of

239 bosis (RR, 1.26; 95% CI, 0.86-1.85; P=0.24), cardiac death (RR, 1.01; 95% CI, 0.79-1.30; P=0.91), and

240 95% confidence interval [CI], 1.28-3.70) and cardiac death (RR, 1.39; 95% CI, 1.04-1.86) during follo

241 current therapeutic era, the risk for sudden cardiac death (SCD) after non-ST-segment elevation acute

242 lthough cardio-vascular incidents and sudden cardiac death (SCD) are among the leading causes of prem

243 Sudden cardiac arrest and sudden cardiac death (SCD) are terms often used interchangeably

244 Most sudden cardiac death (SCD) events occur in the general populati

245 Sudden cardiac death (SCD) from arrhythmias is a leading cause

246 Although the occurrence of sudden cardiac death (SCD) in a young person is a rare event, i

247 Accurate knowledge of causes of sudden cardiac death (SCD) in athletes and its precipitating fa

248 The incidence and cause of sudden cardiac death (SCD) in athletes is debated with hypertro

249 ardiographic parameters as markers of sudden cardiac death (SCD) in BrS.

250 The risk of sudden cardiac death (SCD) in patients with heart failure after

251 yopathy for the primary prevention of sudden cardiac death (SCD) in those with a left ventricular eje

252 Sudden cardiac death (SCD) is a devastating event afflicting 35

253 Sudden cardiac death (SCD) is a major cause of mortality in adu

254 Sudden cardiac death (SCD) is the leading cause of mortality in

255 Sudden cardiac death (SCD) is the most devastating manifestatio

256 Arrhythmic sudden cardiac death (SCD) may be caused by ventricular tachyca

257 d the echocardiographic predictors of sudden cardiac death (SCD) within 2 population-based cohorts.

258 disease carries an elevated risk for sudden cardiac death (SCD), and implantable cardioverter-defibr

259 syndromes are at an increased risk of sudden cardiac death (SCD).

260 hic cardiomyopathy is associated with sudden cardiac death (SCD).

261 essed whether it is a risk factor for sudden cardiac death (SCD).

262 ed in approximately 80% of victims of sudden cardiac death (SCD).

263 ar arrhythmia is the leading cause of sudden cardiac death (SCD).

264 of the QT interval is associated with sudden cardiac death (SCD).

265 rotein leads to an increased risk for sudden cardiac death (SCD).

266 dividuals account for the majority of sudden cardiac deaths (SCDs).

267 between baseline WBC and MACE (composite of cardiac death, stent thrombosis, spontaneous myocardial

268 noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction [TVMI

269 utcome was target lesion failure, defined as cardiac death, target vessel myocardial infarction, and

270 was the device-oriented composite end point (cardiac death, target vessel myocardial infarction, and

271 nferiority) was target vessel failure (TVF) (cardiac death, target vessel myocardial infarction, and

272 vessel failure, defined as the composite of cardiac death, target vessel myocardial infarction, or i

273 (TLF; device-oriented composite end point of cardiac death, target vessel myocardial infarction, or i

274 Target vessel failure (TVF), a composite of cardiac death, target vessel-related myocardial infarcti

275 point of target lesion failure (composite of cardiac death, target vessel-related myocardial infarcti

276 g-term target-vessel failure (a composite of cardiac death, target-vessel myocardial infarction, and

277 a device-oriented composite endpoint (DOCE)-cardiac death, target-vessel myocardial infarction, or c

278 failure, which was defined as a composite of cardiac death, target-vessel myocardial infarction, or i

279 nt was target-vessel failure (a composite of cardiac death, target-vessel myocardial infarction, or t

280 ad a lower risk of myocardial infarction and cardiac death than did those with a troponin concentrati

281 risk of subsequent myocardial infarction or cardiac death than those with normal renal function (24%

282 to the pandemics of heart failure and sudden cardiac death, thus calling for a reappraisal of the mec

283 Experience with uncontrolled donors after cardiac death (uDCD), that is, donors with an unexpected

284 Patients with an increased risk of sudden cardiac death undergo cardioverter-defibrillator implant

285 circulatory support/transplantation, sudden cardiac death, vascular outcomes in coarctation of the a

286 was a composite of prospectively adjudicated cardiac death, vessel-related myocardial infarction, ves

287 In contrast, nonsudden cardiac death was associated with a higher resting heart

288 Sudden cardiac death was not observed in young pigs; however, L

289 yet a tendency toward a protective effect on cardiac death was observed (RR, 0.78; 95% CI, 0.60-1.03)

290 Risk of cardiac death was similar between the 2 groups.

291 ation with hospitalization for heart failure/cardiac death was tested by multivariable Cox regression

292 rs (ICDs) for secondary prevention of sudden cardiac death were conducted nearly 2 decades ago and en

293 The most common explained causes of sudden cardiac death were coronary artery disease (24% of cases

294 A total of 490 cases of sudden cardiac death were identified.

295 Subsequent type 1 myocardial infarction and cardiac death were reported at 1 year.

296 Cardiac deaths were classified as sudden cardiac, relate

297 Overall, 181 cardiac deaths were observed, which was 3.4 times that e

298 as stroke, myocardial infarction, or sudden cardiac death, were assessed prospectively over a 10-yea

299 After sudden cardiac death with negative autopsy, clinical screening

300 hose at low risk of myocardial infarction or cardiac death within 30 days.